A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

Inclusion Criteria: * Participants with prescriptions in deucravacitinib or any biologics as comparator group during the indexing period. * Participants with at least one confirmed diagnosis of disease code for psoriasis within 12 months prior to the index date. * Aged 18 years or older at the index date Exclusion Criteria: * Participants with prescription in deucravacitinib or any biologics as comparator group prior to the index date. * Participants with fewer than 12 months of available claim records prior to the index date. * Participants with no claims record within 1-year after the index date (no visit after the index date). * Specific for serious infection: Participants who had at least one disease code of hospitalized infection in the 60 days period before the index date. * Specific for malignancy: Participants who had at least one disease code of malignancy prior to the index date